Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties from compounding the drug. Our FDA/Food, Drug & Device and Health Care Groups have developed an initial checklist for providers to consider during the FDA’s enforcement discretion period….
By: Alston & Bird
By: Alston & Bird